THG 113

Drug Profile

THG 113

Alternative Names: PDC-31; PDC-41; PHG 113; THG113.31

Latest Information Update: 14 Mar 2016

Price : $50

At a glance

  • Originator Theratechnologies
  • Developer PDC Biotech
  • Class Peptides
  • Mechanism of Action Prostaglandin F2 alpha antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Dysmenorrhoea; Preterm labour

Most Recent Events

  • 10 Dec 2012 PDC Biotech completes a phase I trial in Dysmenorrhoea in Austria and Germany (NCT01250587)
  • 24 Jan 2012 Phase-I development is ongoing in Austria and Germany
  • 12 May 2008 THG 113 licensed to PDC Biotech worldwide for the treatment of Dysmenorrhoea and prevention of Preterm labour
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top